Immunotherapy Improves Prognosis of Babies With Leukemia Less Oncology Times. 45(10):1,18, May 20, 2023. Favorite PDF Permissions Free
Safe Regimen for Patients Undergoing Stem Cell Transplantation Kumar Das, Dibash Kumar Das, Dibash Less Oncology Times. 45(8):21, April 20, 2023. Favorite PDF Permissions Free
In-House Technology Used to Expedite Delivery of CAR-T Therapy Froelich, Warren Froelich, Warren Less Oncology Times. 45(8):1,10, April 20, 2023. Favorite PDF Permissions Free
Key Molecule in Progression of Chronic Myeloproliferative Neoplasms Kumar Das, Dibash Kumar Das, Dibash Less Oncology Times. 45(7):20, April 5, 2023. Favorite PDF Permissions Free
Ponatinib Outperforms Imatinib in Newly Diagnosed Ph+ALL Leukemia Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 45(7):16, April 5, 2023. Favorite PDF Permissions Free
Genomics-Based Diagnoses & Precision Therapies in Myeloid Neoplasms Kumar Das, Dibash Kumar Das, Dibash Less Oncology Times. 45(7):1,10,18, April 5, 2023. Favorite PDF Permissions Free
Olutasidenib (Rezlidhia™) Lovell, Alexandra Lovell, Alexandra Less Oncology Times. 45(6):8, March 20, 2023. Favorite PDF Permissions Free
Chemotherapy De-Escalation Factors in Acute Lymphoblastic Leukemia Goodwin, Peter M. Goodwin, Peter M. Less Oncology Times. 45(5):1,13, March 5, 2023. Favorite PDF Permissions Free
Olverembatinib Demonstrates Promising Results in T315I-Mutant CML Kumar Das, Dibash Kumar Das, Dibash Less Oncology Times. 45(4):1,15,25, February 20, 2023. Favorite PDF Permissions Free
Food Insecurity Among Families of Children With Leukemia Nalley, Catlin Nalley, Catlin Less Oncology Times. 45(3):29, February 5, 2023. Favorite PDF Permissions Free
Exploring a New Path to Differentiation Therapy for Acute Myeloid Leukemia Neff Newitt, Valerie Neff Newitt, Valerie Less Oncology Times. 45(3):1,17-18, February 5, 2023. Favorite PDF Permissions Free
Zanubrutinib Shows Superior Efficacy With Fewer Side Effects Than Ibrutinib Froelich, Warren Froelich, Warren Less Oncology Times. 45(3):1,14, February 5, 2023. Favorite PDF Permissions Free
3 QUESTIONS ON . . . Whether Leukemia & Myeloma Trials Represent Patients at Risk: With Jorge Cortes, MD, Director of the Georgia Cancer Center at Augusta University DiGiulio, Sarah DiGiulio, Sarah Less Oncology Times. 45(2):26, January 20, 2023. Favorite PDF Permissions Free
Novel Triplet Approach Demonstrates Effectiveness & Safety in CLL Kumar Das, Dibash Kumar Das, Dibash Less Oncology Times. 45(2):16, January 20, 2023. Favorite PDF Permissions Free
New Trial Results Change Practice for Acute Lymphoblastic Leukemia Less Oncology Times. 45(2):1,14, January 20, 2023. Favorite PDF Permissions Free
New Regimen Reduces Relapse in Aggressive T-Cell Malignancies Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 45(1):1,19, January 5, 2023. Favorite PDF Permissions Free
Insights Into the Significant Cost Increase in Pediatric ALL Care Kumar Das, Dibash Kumar Das, Dibash Less Oncology Times. 44(24):32, December 20, 2022. Favorite PDF Permissions Free
Ponatinib Demonstrates High Response Rates & Robust Survival Outcomes in Patients With CP-CML Kumar Das, Dibash Kumar Das, Dibash Less Oncology Times. 44(24):1,24, December 20, 2022. Favorite PDF Permissions Free
NCCN Highlights New Treatment Advances in Blood Cancer Holt, Chuck Holt, Chuck Less Oncology Times. 44(23):1,17, December 5, 2022. Favorite PDF Permissions Free
Epigenetic Transcriptional Control Module Reveals Possible AML Therapy Kumar Das, Dibash Kumar Das, Dibash Less Oncology Times. 44(22):33-34, November 20, 2022. Favorite PDF Permissions Free
The Genomic Landscape of Pediatric Acute Lymphoblastic Leukemia Kumar Das, Dibash Kumar Das, Dibash Less Oncology Times. 44(22):11, November 20, 2022. Favorite PDF Permissions Free
Sorafenib + Standard Chemotherapy in Pediatric Patients With FLT3/ITD+ AML Kumar Das, Dibash Kumar Das, Dibash Less Oncology Times. 44(21):17, November 5, 2022. Favorite PDF Permissions Free
CD123-Targeted Therapy Shows Long-Term Benefit for BPDCN Patients Nalley, Catlin Nalley, Catlin Less Oncology Times. 44(21):1,7, November 5, 2022. Favorite PDF Permissions Free
New Mutation Identified May Define High-Risk Subtype of Pediatric AML Kumar Das, Dibash Kumar Das, Dibash Less Oncology Times. 44(19):1,9, October 5, 2022. Favorite PDF Permissions Free
Common Drug Activates Oncogene of MDS & Leukemia Gallagher, Amy Gallagher, Amy Less Oncology Times. 44(18):22, September 20, 2022. Favorite PDF Permissions Free
Outcomes Worse for Black Adolescent & Young Adult Patients With AML Holt, Chuck Holt, Chuck Less Oncology Times. 44(17):21, September 5, 2022. Favorite PDF Permissions Free
Higher Doses of CAR-T Therapy Bring Survival Advantage for B-ALL Patients Less Oncology Times. 44(17):1,11, September 5, 2022. Favorite PDF Permissions Free
Mediator Probe PCR for Personalized MRD Monitoring of ALL Kumar Das, Dibash Kumar Das, Dibash Less Oncology Times. 44(16):17, August 20, 2022. Favorite PDF Permissions Free
Brexucabtagene Autoleucel (Tecartus™) Lovell, Alexandra Lovell, Alexandra Less Oncology Times. 44(16):10, August 20, 2022. Favorite PDF Permissions Free
Young Black Patients With AML Face Significantly Worse Outcomes Less Oncology Times. 44(15):1,12, August 5, 2022. Favorite PDF Permissions Free
A New Look at the Formation of Blood Less Oncology Times. 44(14):1,16, July 20, 2022. Favorite PDF Permissions Free
Addressing Disparities in CAR T-Cell Therapy Trials Kumar Das, Dibash Kumar Das, Dibash Less Oncology Times. 44(14):1,12, July 20, 2022. Favorite PDF Permissions Free
Adolescent & Young Adult Leukemia Survivors Have Shorter Life Span Less Oncology Times. 44(12):1,14, June 20, 2022. Favorite PDF Permissions Free
The Use of Venetoclax + Azacitidine for Acute Myeloid Leukemia & IDH1/2 Mutations Kumar Das, Dibash Kumar Das, Dibash Less Oncology Times. 44(10):1,22, May 20, 2022. Favorite PDF Permissions Free
First Comprehensive Map Of Human Blood Stem Cell Development Less Oncology Times. 44(9):1,10, May 5, 2022. Favorite PDF Permissions Free
Advancing Therapies for Myelodysplastic Syndromes Kumar Das, Dibash Kumar Das, Dibash Less Oncology Times. 44(9):1,6, May 5, 2022. Favorite PDF Permissions Free
Asciminib (Scemblix®) Hofherr, Mara Lacy Hofherr, Mara Lacy Less Oncology Times. 44(8):17,32, April 20, 2022. Favorite PDF Permissions Free
Study Helps Explain Sex Bias, Mechanisms of Rare Leukemia Holt, Chuck Holt, Chuck Less Oncology Times. 44(7):14, April 5, 2022. Favorite PDF Permissions Free
Study Solves Protein Structure, Shows How Mutation Drives Blood Cancers Less Oncology Times. 44(7):1,21, April 5, 2022. Favorite PDF Permissions Free
Changes in Patterns of Care for Frontline AML Treatment in Older Adults Kumar Das, Dibash Kumar Das, Dibash Less Oncology Times. 44(6):1,23, March 20, 2022. Favorite PDF Permissions Free
The Incredible Story of Emily Whitehead & CAR T-Cell Therapy Neff Newitt, Valerie Neff Newitt, Valerie Less Oncology Times. 44(6):1,19-21, March 20, 2022. Favorite PDF Permissions Free
Review of a New Multigenic Autologous CAR T-Cell Therapy Nolen, Lindsey Nolen, Lindsey Less Oncology Times. 44(5):1,17, March 5, 2022. Favorite PDF Permissions Free
Exploring Creative Drug Combinations as a Path to Better Patient Outcomes Neff Newitt, Valerie Neff Newitt, Valerie Less Oncology Times. 44(5):1,14, March 5, 2022. Favorite PDF Permissions Free
Improving Outcomes in Blast Phase Chronic Myeloid Leukemia Kumar Das, Dibash Kumar Das, Dibash Less Oncology Times. 44(4):1,20, February 20, 2022. Favorite PDF Permissions Free
Survival Rates of Adult Patients With Relapsed ALL After Hematopoietic Cell Transplantation Less Oncology Times. 44(3):1,22, February 5, 2022. Favorite PDF Permissions Free
Producing & Using Anti-CD19 CAR T Cells Against B-Cell Malignancies Less Oncology Times. 44(2):24, January 20, 2022. Favorite PDF Permissions Free
Expert Perspective: Evaluating Ibrutinib in High-Risk Hairy Cell Leukemia Kumar Das, Dibash Kumar Das, Dibash Less Oncology Times. 44(2):1,13, January 20, 2022. Favorite PDF Permissions Free
3 QUESTIONS ON... A New Drug Combo for Kids With APL: With Matthew Kutny, MD, of Children's of Alabama and the University of Alabama at Birmingham DiGiulio, Sarah DiGiulio, Sarah Less Oncology Times. 44(1):34, January 5, 2022. Favorite PDF Permissions Free
DNA Sequencing to Predict Leukemia Relapse After CAR-T Therapy Froelich, Warren Froelich, Warren Less Oncology Times. 44(1):1,18, January 5, 2022. Favorite PDF Permissions Free
Improving Care & Life for Cancer Patients With CLL Neff Newitt, Valerie Neff Newitt, Valerie Less Oncology Times. 43(23):19-20, December 5, 2021. Favorite PDF Permissions Free
Progress in Leukemia in 2021: An Optimistic Perspective Kantarjian, Hagop Kantarjian, Hagop Less Oncology Times. 43(23):1,13-17, December 5, 2021. Favorite PDF Permissions Free
Double-Vaccinated Blood Cancer Patients Have Poor Immune Response Against COVID-19 Less Oncology Times. 43(22):1,15, November 20, 2021. Favorite PDF Permissions Free
Detection & Treatment of AML Via Deep Learning & Population Genetics Kumar Das, Dibash Kumar Das, Dibash Less Oncology Times. 43(21):18, November 5, 2021. Favorite PDF Permissions Free
TET2: A Promising Therapeutic Target for Pediatric T-ALL Kumar Das, Dibash Kumar Das, Dibash Less Oncology Times. 43(21):1,12, November 5, 2021. Favorite PDF Permissions Free
How Artificial Intelligence Can Help Diagnose Leukemia Less Oncology Times. 43(20):1,15, October 20, 2021. Favorite PDF Permissions Free
Benefits of Immunotherapy After High-Dose Chemo in AML Less Oncology Times. 43(19):26, October 5, 2021. Favorite PDF Permissions Free
Advances in Off-the-Shelf Immunotherapy: Expert Discussion Kumar Das, Dibash Kumar Das, Dibash Less Oncology Times. 43(19):12-13, October 5, 2021. Favorite PDF Permissions Free CME Test
A New Risk Factor for Acute Lymphoblastic Leukemia Less Oncology Times. 43(19):1,16, October 5, 2021. Favorite PDF Permissions Free
Genomic Markers of Aggressive Childhood Leukemias Identified Less Oncology Times. 43(18):27, September 20, 2021. Favorite PDF Permissions Free
Combination Therapy Provides Remission for Chronic Lymphocytic Leukemia LaCorte, Sarah LaCorte, Sarah Less Oncology Times. 43(18):21-22, September 20, 2021. Favorite PDF Permissions Free
The Correlation Between Transplant & Survival in Philadelphia-Like ALL Neff Newitt, Valerie Neff Newitt, Valerie Less Oncology Times. 43(17):15-16, September 5, 2021. Favorite PDF Permissions Free
Adolescent & Young Adult Enrollment in NCI-Sponsored Clinical Trials Less Oncology Times. 43(17):1,14, September 5, 2021. Favorite PDF Permissions Free
Acute Lymphoblastic Leukemia: Research & Therapy in 2021 Kantarjian, Hagop; Jabbour, Elias Kantarjian, Hagop; Jabbour, Elias Less Oncology Times. 43(17):1,11,12,18, September 5, 2021. Favorite PDF Permissions Free
Ficlatuzumab + Chemo in Relapsed/Refractory Acute Myeloid Leukemia Gallagher, Amy Gallagher, Amy Less Oncology Times. 43(16):1,15, August 20, 2021. Favorite PDF Permissions Free
Mechanisms That Create Individualized Metabolism in Leukemia Less Oncology Times. 43(15):1,13, August 5, 2021. Favorite PDF Permissions Free
Mechanism of Leukemia Pathogenesis & Possible Targeted Therapy Holt, Chuck Holt, Chuck Less Oncology Times. 43(15):1,7, August 5, 2021. Favorite PDF Permissions Free
Exploring the Link Between Inflammation & Leukemia Less Oncology Times. 43(14):1,12, July 20, 2021. Favorite PDF Permissions Free
Understanding Tolerance for Imatinib Nonadherence Among CML Patients Nalley, Catlin Nalley, Catlin Less Oncology Times. 43(13):34, July 5, 2021. Favorite PDF Permissions Free
Blood Cancer Patients With COVID-19 Fare Better With Convalescent Plasma Less Oncology Times. 43(13):1,12, July 5, 2021. Favorite PDF Permissions Free
Combination Therapy Achieves High Response Rates in ALL Less Oncology Times. 43(12):34, June 20, 2021. Favorite PDF Permissions Free
Beating Leukemia With a Healthy Diet Change Less Oncology Times. 43(11):1,17, June 5, 2021. Favorite PDF Permissions Free
MRD-Positive AML Patients Should Not Proceed Directly to Transplant Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 43(8):36, April 20, 2021. Favorite PDF Permissions Free
More Strategies Needed to Eradicate Minimal Residual Disease in AML Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 43(8):34, April 20, 2021. Favorite PDF Permissions Free
Deep Learning & Imaging Flow Cytometry for ALL Monitoring Kumar Das, Dibash Kumar Das, Dibash Less Oncology Times. 43(7):1,14,17, April 5, 2021. Favorite PDF Permissions Free
Reproducing Acute Lymphoblastic Leukemia Surface & Genetic Markers in Cells Holt, Chuck Holt, Chuck Less Oncology Times. 43(5):1,12, March 5, 2021. Favorite PDF Permissions Free
New Maintenance Treatment for Acute Myeloid Leukemia Prolongs Lives Less Oncology Times. 43(4):26, February 20, 2021. Favorite PDF Permissions Free
Scientists Create On-Off Switches to Control CAR T-Cell Activity Less Oncology Times. 43(4):1,12, February 20, 2021. Favorite PDF Permissions Free
Novel Combination Therapy May Help Overcome mTOR Drug Resistance in AML Less Oncology Times. 43(2):24, January 20, 2021. Favorite PDF Permissions Free
Decitabine/Cedazuridine (Inqovi®) Lovell, Alexandra Lovell, Alexandra Less Oncology Times. 43(2):15, January 20, 2021. Favorite PDF Permissions Free
Venetoclax Combination Improves Outcomes for Patients With Mutated AML Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 43(2):1,12, January 20, 2021. Favorite PDF Permissions Free
Precision Medicine Advances Positive Outcomes in AML Byrd, John C. Byrd, John C. Less Oncology Times. 43(2):1,11, January 20, 2021. Favorite PDF Permissions Free
Chemotherapy Plus Blinatumomab Improves Survival for B-Cell ALL Patients Less Oncology Times. 43(1):1,6, January 5, 2021. Favorite PDF Permissions Free
Young Survivors of Acute Myeloid Leukemia Have Long-Term Complications Less Oncology Times. 42(24):83-84, December 20, 2020. Favorite PDF Permissions Free
Advances in Pediatric Acute Lymphoblastic Leukemia Treatment Simoneaux, Richard Simoneaux, Richard Less Oncology Times. 42(24):6-7, December 20, 2020. Favorite PDF Permissions Free CME Test
Reducing GVHD While Retaining Anti-Cancer Effects Less Oncology Times. 42(23):29, December 5, 2020. Favorite PDF Permissions Free
Findings Show Superior Patient Outcomes in Beat AML Clinical Trial Less Oncology Times. 42(23):1,16, December 5, 2020. Favorite PDF Permissions Free
What Clinicians Treating MDS Patients Must Understand About the TP53 Gene Conick, Hal Conick, Hal Less Oncology Times. 42(21):1,10, November 5, 2020. Favorite PDF Permissions Free
Azacitidine Tablets (Onureg®) Shultes, Kendall C. Shultes, Kendall C. Less Oncology Times. 42(20):11,35, October 20, 2020. Favorite PDF Permissions Free
A Promising Way to Stop Leukemia Relapse Found in New Research Less Oncology Times. 42(19):1,14, October 5, 2020. Favorite PDF Permissions Free
A New Standard of Care for Acute Myeloid Leukemia Holt, Chuck Holt, Chuck Less Oncology Times. 42(19):1,6,14, October 5, 2020. Favorite PDF Permissions Free
3 QUESTIONS ON... The Long-Term Benefits of Risk-Stratified Therapy for Childhood ALL: With Stephanie Dixon, MD, of St. Jude Children's Research Hospital DiGiulio, Sarah DiGiulio, Sarah Less Oncology Times. 42(18):50, September 20, 2020. Favorite PDF Permissions Free
New Clinical Practice Guidelines on AML in Older Adults Less Oncology Times. 42(17):1,14, September 5, 2020. Favorite PDF Permissions Free
Dual Inhibitor May Be Safer for Chronic Lymphocytic Leukemia Patients Less Oncology Times. 42(15):30, August 5, 2020. Favorite PDF Permissions Free
Pathogens Suppress Immune Response With Molecule Less Oncology Times. 42(15):1,29, August 5, 2020. Favorite PDF Permissions Free
Long-Term Results Support Efficacy of Ublituximab + Ibrutinib in High-Risk CLL Nalley, Catlin Nalley, Catlin Less Oncology Times. 42(14):36, July 20, 2020. Favorite PDF Permissions Free
Long-Term Results Support Efficacy of Ublituximab + Ibrutinib in High-Risk CLL Nalley, Catlin Nalley, Catlin Less Oncology Times. 42(14):36, July 20, 2020. Favorite PDF Permissions Free
Precision Medicine Treatments for Children With Leukemia Less Oncology Times. 42(14):1,9, July 20, 2020. Favorite PDF Permissions Free
Precision Medicine Treatments for Children With Leukemia Less Oncology Times. 42(14):1,9, July 20, 2020. Favorite PDF Permissions Free
Initial Findings Show Promise of Triplet Therapy in CLL Nalley, Catlin Nalley, Catlin Less Oncology Times. 42(13):35, July 5, 2020. Favorite PDF Permissions Free
Initial Findings Show Promise of Triplet Therapy in CLL Nalley, Catlin Nalley, Catlin Less Oncology Times. 42(13):35, July 5, 2020. Favorite PDF Permissions Free
